Biocon share price rose up 2% in the early trade on June 1 after the company received a favorable ruling from US patent and Trademark Appeal Board (US PTAB).

 The US Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan, Biocon's partner in inter partes review (IPR) proceeding to find all challenged claims of Sanofi's Lantus SoloSTAR device patents, U.S. patent Nos. 8,603,044, 8,992,486, and 9,526,844unpatentable.

 The PTAB found three claims of the 9,604,008 patent patentable and two claims to be patentable.

 However, Mylan and Biocon have previously obtained a covenant not to sue from Sanofi' on the '008 patent and therefore this ruling does not impact Biocon and Mylan's ability to commercialize Semglee upon final approval from the US Food and Drug Administration.

 The PTAB also found Sanofi's proposed amended claims for the '486 and '844 patents patentable. 

 At 9:26 hours, Biocon was quoting at Rs 358.75, up Rs 4.05, or 1.14% on the BSE.